Análise do uso inadequado de medicamentos para o tratamento da obesidade e suas implicações clínicas: Uma revisão abrangente

This study addresses the risks associated with the inappropriate, indiscriminate use and self-medication of weight-loss drugs and appetite suppressants, such as sibutramine and fenproporex. The central issue lies in the high consumption of these substances, driven by millions of prescriptions and the irregular marketing of compounded products containing mixtures of amphetamines, diuretics, and laxatives, which leads to a significant increase in emergency care visits due to poisoning and metabolic imbalances. Findings from the literature demonstrate that such centrally acting drugs can trigger clinical manifestations ranging from agitation, insomnia, tachycardia, and hypertensive crises to severe complications, such as cardiac arrhythmias, seizures, myocardial infarction, and an approximately 16% increase in the risk of major cardiovascular events. As coping measures, the study highlights the imperative need for stricter dispensing controls and the strengthening of health regulation. It is concluded that a multidisciplinary approach, integrating physicians and pharmacists, combined with health education, regular clinical monitoring, and public awareness campaigns, is essential to ensure efficacy and safety in the treatment of obesity, mitigating the risks associated with the use of these drugs.

Authors

Publication Details

Journal
Revista fisio&terapia.
Published
2026-11-13
DOI
https://doi.org/10.69849/pn8dem72
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Análise do uso inadequado de medicamentos para o tratamento da obesidade e suas implicações clínicas: Uma revisão abrangente

Tatiana Lagoa, Amanda Castro de Paula, Bianca Pacheco Souza
2 links
Revista fisio&terapia.
Pharmacology and Obesity Treatment
article

Análise do uso inadequado de medicamentos para o tratamento da obesidade e suas implicações clínicas: Uma revisão abrangente

Tatiana Lagoa, Amanda Castro de Paula, Bianca Pacheco Souza
article en

Abstract

This study addresses the risks associated with the inappropriate, indiscriminate use and self-medication of weight-loss drugs and appetite suppressants, such as sibutramine and fenproporex. The central issue lies in the high consumption of these substances, driven by millions of prescriptions and the irregular marketing of compounded products containing mixtures of amphetamines, diuretics, and laxatives, which leads to a significant increase in emergency care visits due to poisoning and metabolic imbalances. Findings from the literature demonstrate that such centrally acting drugs can trigger clinical manifestations ranging from agitation, insomnia, tachycardia, and hypertensive crises to severe complications, such as cardiac arrhythmias, seizures, myocardial infarction, and an approximately 16% increase in the risk of major cardiovascular events. As coping measures, the study highlights the imperative need for stricter dispensing controls and the strengthening of health regulation. It is concluded that a multidisciplinary approach, integrating physicians and pharmacists, combined with health education, regular clinical monitoring, and public awareness campaigns, is essential to ensure efficacy and safety in the treatment of obesity, mitigating the risks associated with the use of these drugs.

Revista fisio&terapia.Vol. 30(164)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon